SM Life Science(50,900 -4.14%)Announced on the 7th that Coimune has won a contract for development and production of pharmaceutical products (CDMO) from Immunonomic Therapeutics. Coimune, SCM Life Science Department, Genexine(119,500 -0.99%)Is a joint venture in the United States.
Coimune will be in charge of the development and production of Immunomic’s’ITI-1020′ under this contract. ITI-1020 is a messenger ribonucleic acid (mRNA)-based immune anticancer drug targeting glioblastoma. Coimune has secured conditions to receive technical fees (milestones) for each stage related to the development of ITI-1020 and part of the sales amount for commercialization as ordinary technology usage fees (royalties).
According to the company, ahead of the signing of this contract, Immunomic highly evaluated Coimune’s excellent pharmaceutical manufacturing and quality control standards (cGMP) manufacturing capabilities. Coimune has cGMP manufacturing facilities including 10 ISO-7 facilities and 4 quality control (QC) laboratories on approximately 560 pyeong of land in North Carolina, USA.
“We are pleased to be able to cooperate with Immunom, which has new and professional technologies,” said Charles Nicolet Coimune, CEO. I look forward to it.”
Immunomic is an American bio company that develops immune cell therapy products based on the immune vaccine platform’UNITE’. HLB, a Korean KOSDAQ listed company in February last year(97,000 -0.10%)Acquired a 51% stake in Immunomics and incorporated it into a subsidiary.
The UNITE platform is a technology that can enhance the function of human immune cells by targeting and acting on specific antigens. Immunomic is developing immune cell therapy that can be applied to cancer, allergies, and other infectious diseases using UNITE.
Reporter Park In-hyuk [email protected]
Ⓒ Hankyung.com prohibits unauthorized reproduction and redistribution